| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Tetrakis(triphenylphosphine)platinum(0) has been investigated for its potential use in cancer treatment. As a platinum complex, it may interact with DNA and proteins similar to other platinum-based anticancer agents. However, its primary applications are in catalysis rather than as a therapeutic agent. The compound's biological activity is primarily through its ability to participate in catalytic reactions relevant to biological systems. Its role in carbon-carbon bond formation makes it valuable for synthesizing complex organic molecules including potential drug candidates.
|
|---|---|
| ln Vitro |
In vitro, tetrakis(triphenylphosphine)platinum(0) is used primarily as a catalyst in organic reactions rather than as a direct cell-modulating agent. It has been investigated for potential use in cancer treatment. The compound serves as a biochemical reagent that can be used as a biomaterial for life science research. Its catalytic activity in carbon-carbon bond formation makes it valuable for synthesizing complex organic molecules. Cellular assays are not typically performed with this compound as a standalone agent, though its catalytic products may be evaluated.
|
| ln Vivo |
In vivo data for tetrakis(triphenylphosphine)platinum(0) is limited, as it is primarily a catalyst and research reagent. The compound has been investigated for potential use in cancer treatment. However, it is classified for research use only and is not intended for human or veterinary applications. Any in vivo studies would likely be toxicological evaluations or studies on platinum-containing compounds. The compound's primary value lies in its use as a catalyst for organic synthesis and drug discovery, with in vivo studies being conducted on the final pharmaceutical products synthesized using this catalyst rather than on the catalyst itself.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for tetrakis(triphenylphosphine)platinum(0) are not typically performed, as it is a catalyst rather than a receptor-targeting agent. The compound's primary applications are in organic synthesis, particularly in carbon-carbon bond formation reactions. A typical assay involves using the compound as a catalyst in reactions such as hydrogenation, hydrosilylation, or cross-coupling. The compound is typically dissolved in organic solvents such as toluene or THF and used at catalytic concentrations (typically 0.1-5 mol%). Reaction progress is monitored by TLC, GC, or HPLC. Catalyst activity and selectivity are evaluated by product yield and purity.
|
| Cell Assay |
Cellular assays for tetrakis(triphenylphosphine)platinum(0) are not standard, as the compound is primarily a catalyst rather than a direct cell-modulating agent. The compound has been investigated for potential use in cancer treatment, but specific cellular assay protocols are not readily available in the public literature. Any cellular studies would likely evaluate the effects of platinum-containing compounds synthesized using this catalyst. The compound is classified as a biochemical reagent for research use only and is not typically used in standard cell-based screening assays.
|
| Animal Protocol |
In vivo animal studies for tetrakis(triphenylphosphine)platinum(0) are not standard, as it is primarily a catalyst rather than a therapeutic candidate. The compound has been investigated for potential use in cancer treatment, but specific in vivo protocols are not readily available in the public literature. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would likely evaluate platinum-containing compounds synthesized using this catalyst. The compound's primary value lies in its use as a catalyst for organic synthesis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tetrakis(triphenylphosphine)platinum(0) is limited, as it is primarily a catalyst rather than a pharmaceutical agent. The compound is a solid at room temperature. As a platinum complex with large lipophilic triphenylphosphine ligands, it is expected to have high lipophilicity and strong protein binding. The compound is typically stored under inert atmosphere due to air sensitivity. Specific ADME data is not available in the public literature. The compound's applications are limited to organic synthesis and catalysis.
|
| Toxicity/Toxicokinetics |
Toxicological data for tetrakis(triphenylphosphine)platinum(0) is limited, as it is primarily a catalyst. As a platinum compound, it may exhibit toxicity similar to other platinum-containing compounds. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored under inert atmosphere away from air and moisture. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed.
|
| Additional Infomation |
Tetrakis(triphenylphosphine)platinum(0) (CAS 14221-02-4) is a biochemical reagent and organometallic compound used as a catalyst in organic synthesis. It has a molecular formula of C₇₂H₆₀P₄Pt. The compound is used in carbon-carbon bond formation reactions for the synthesis of pharmaceuticals and fine chemicals. It is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. The compound is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis.
|
| Molecular Formula |
C72H60P4PT
|
|---|---|
| Molecular Weight |
1244.22
|
| Exact Mass |
1243.329
|
| CAS # |
14221-02-4
|
| PubChem CID |
11979705
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
360ºC at 760 mmHg
|
| Flash Point |
181.7ºC
|
| LogP |
13.776
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
77
|
| Complexity |
202
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Pt].P(C1C([H])=C([H])C([H])=C([H])C=1[H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C([H])=C([H])C=1[H].P(C1C([H])=C([H])C([H])=C([H])C=1[H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C([H])=C([H])C=1[H].P(C1C([H])=C([H])C([H])=C([H])C=1[H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C([H])=C([H])C=1[H].P(C1C([H])=C([H])C([H])=C([H])C=1[H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
SYKXNRFLNZUGAJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/4C18H15P.Pt/c4*1-4-10-16(11-5-1)19(17-12-6-2-7-13-17)18-14-8-3-9-15-18;/h4*1-15H;
|
| Chemical Name |
platinum;triphenylphosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8037 mL | 4.0186 mL | 8.0372 mL | |
| 5 mM | 0.1607 mL | 0.8037 mL | 1.6074 mL | |
| 10 mM | 0.0804 mL | 0.4019 mL | 0.8037 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
